Pipeline

Genetic Immunity's pipeline products are based on the experience and know-how gained during the development of DermaVir Patch, a topically administered HIV Nanomedicine candidate designed to amplify the immune system to specifically kill HIV-infected cells.

Immune Therapy for Dust Mite Allergy

Genetic Immunity is leveraging its nanomedicine immune amplification platform technology to develop DermAll Patch. A Nanomedicine nanoparticle is formulated with a plasmid DNA encoding a special allergen. Repeated administration of the DermAll Patch treatment has the potential to control allergy similar to DermaVir Patch treatment for HIV/AIDS.

The DermAll Patch development program is a collaboration with University Szeged, which is currently evaluating the product candidate in a mouse model.

Immune Therapy for Chlamydia Infection

Genetic Immunity is leveraging its nanomedicine immune amplification platform technology to develop ChlamyDerm Patch against Chlamydia Infection. A Nanomedicine nanoparticle is formulated with a plasmid DNA encoding the special antigens of Chlamydia pneumoniae, an intracellular bacterium.

The ChlamyDerm Patch development program is a collaboration with University Semmelweis, which is currently evaluating the product candidate in a mouse model.

Immune Therapies for Cancer

Genetic Immunity's immune therapy technology platform is potentially applicable for the development of new cancer theraphy utilising plasmid DNA encoding tumor-specific antigens.

Human papilomavirus is one of the major causes of cervical cancer. Genetic Immunity designed a plasmid DNA expressing the appropriate HPV sequences. The HPV nanomedicine candidate - HuPaDerm - is expected to induce HPV-specific precursor T-cells that can proliferate and kill tumor cells harboring the virus.